Severe neonatal infection adaptive platform trials in Africa
SNIP-AFRICA aims to establish a clinical research network and architecture to implement adaptive platform trials in sub-Saharan Africa (SSA), responding to the urgent need for improved treatment of childhood infection in an era of...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
FIT-BI
Fully Integrated Technology for rapid and multiplex Bacteria...
212K€
Cerrado
CPP2021-008464
Desarrollo de una nueva herramienta inteligente y predictiva...
769K€
Cerrado
PID2019-109820RB-I00
PLATAFORMA DE IMAGEN MULTI-ESCALA PARA ACELERAR EL DESARROLL...
210K€
Cerrado
ResisCHIP
Rapid chip-based detection of antibiotic resistances
150K€
Cerrado
OUTSMART-infection
Microbiome centered prediction and prevention of recurrent i...
3M€
Cerrado
RTC-2015-3184-1
Nuevas estrategias para el control de infecciones nosocomial...
472K€
Cerrado
Información proyecto SNIP-AFRICA
Duración del proyecto: 60 meses
Fecha Inicio: 2023-06-07
Fecha Fin: 2028-06-30
Líder del proyecto
FONDAZIONE PENTA ETS
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
7M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
SNIP-AFRICA aims to establish a clinical research network and architecture to implement adaptive platform trials in sub-Saharan Africa (SSA), responding to the urgent need for improved treatment of childhood infection in an era of increasing antimicrobial resistance (AMR).
SNIP-AFRICA focuses on the high-burden, high-impact group of inpatient neonates and infants with sepsis. This is a group especially affected by escalating rates of AMR in SSA healthcare facilities contributing to much slower than desirable improvements in neonatal mortality across SSA.
The project will address all aspects of APTs in neonatal sepsis from defining potential treatments of interest to translation into clinical guidance, and will deliver interventional studies in the two domains of neonatal dose confirmation and drug regimen selection. The network and architecture could be readily extended to include older children in hospital with infections with epidemic potential.
SNIP-AFRICA will achieve its aim by bringing together partners from the global North and SSA, including several with experience in designing and running adaptive platform trials and complex randomised controlled trials in SSA. The project therefore builds on existing expertise and capacity to enable an innovative response to the major threat to child health of AMR through a new architecture and extended network. The work plan includes Project Management, Coordination and Communication (WP1), Clinical and Microbiological Surveillance (WP2), Adaptive Platform Core Protocol and Governance (WP3), Pharmacokinetics for Adaptive Platform Trial (WP4), Complex Adaptive Drug Regimen Trial (WP5), Training and Capacity building for Adaptive Trials (WP6) and Stakeholder Engagement and Integration (WP7).
SNIP-AFRICA aims to trigger a paradigm shift in interventional research in severe childhood infection and to equip a network of SSA institutions and researchers to conduct innovative, efficient, targeted research in this area.